Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OCX

OncoCyte (OCX) Stock Price, News & Analysis

OncoCyte logo

About OncoCyte Stock (NASDAQ:OCX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.60
$3.44
52-Week Range
N/A
Volume
100,514 shs
Average Volume
58,260 shs
Market Capitalization
$90.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.06
Consensus Rating
Moderate Buy

Company Overview

OncoCyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

OCX MarketRank™: 

OncoCyte scored higher than 28% of companies evaluated by MarketBeat, and ranked 804th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    OncoCyte has only been the subject of 3 research reports in the past 90 days.

  • Read more about OncoCyte's stock forecast and price target.
  • Earnings Growth

    Earnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for OCX.
  • Dividend Yield

    OncoCyte does not currently pay a dividend.

  • Dividend Growth

    OncoCyte does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OCX.
  • Search Interest

    2 people have searched for OCX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OncoCyte insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.05% of the stock of OncoCyte is held by insiders.

  • Percentage Held by Institutions

    55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OncoCyte's insider trading history.
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

OCX Stock Analysis - Frequently Asked Questions

OncoCyte Corporation (NASDAQ:OCX) issued its earnings results on Monday, May, 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The business earned $2.14 million during the quarter, compared to analyst estimates of $0.13 million. OncoCyte had a negative net margin of 1,516.06% and a negative trailing twelve-month return on equity of 215.59%.
Read the conference call transcript
.

Shares of OncoCyte reverse split before market open on Tuesday, July 25th 2023.The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional investors of OncoCyte include Defender Capital LLC. (0.12%). Insiders that own company stock include Broadwood Partners, LP, Pura Vida Investments, Llc, Andrea S James, Andrew Arno, Alfred D Kingsley, Ronald Asbury Andrews, Andrew J Last and Josh Riggs.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F).

Company Calendar

Last Earnings
5/12/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OCX
CIK
1642380
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$4.00
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.66 million
Net Margins
-1,516.06%
Pretax Margin
-1,514.57%
Return on Equity
-215.59%
Return on Assets
-27.23%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
3.74
Quick Ratio
3.70

Sales & Book Value

Annual Sales
$3.84 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.70) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
28,599,000
Free Float
28,013,000
Market Cap
$90.80 million
Optionable
No Data
Beta
0.97
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:OCX) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners